ArticleJournal of neurology2026
Outcomes of intravenous thrombolysis in patients with acute ischemic stroke and direct oral anticoagulant use within 1 day before stroke onset.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence regarding the outcomes of intravenous thrombolysis (IVT) in patients taking direct oral anticoagulants (DOACs) within 1 day before acute ischemic stroke remains limited. In this study, we aimed to evaluate the bleeding risk after IVT in patients with and without recent DOAC exposure.
methodsThis retrospective cohort study analyzed TriNetX global network data (January 2010-September 2024) in adults aged ≥ 20 years receiving IVT for acute ischemic stroke. Groups with DOAC and no anticoagulant (no-OAC) exposure within 1 day before stroke were compared. The primary outcome was intracranial hemorrhage (ICH) within 2 days after IVT. Secondary outcomes included major bleeding, blood transfusion within 2 days, and 30-day and 90-day mortality rates. Subgroup analyses examined individual DOACs (apixaban, rivaroxaban, edoxaban, and dabigatran). Propensity score matching controlled for confounders with risk differences (RDs) and odds ratios (ORs) to estimate outcome events.
resultsAmong 64,667 patients (mean age 65.1 ± 16.1 years; 50.1% women), 1183 (1.8%) received DOACs, and 63,462 (98.1%) received no anticoagulants. After propensity score matching, the DOAC cohort had lower risks of ICH (RD, - 2.88% [95% CI, - 4.28% to - 1.48%]; OR, 0.36 [95% CI, 0.21-0.60]) and major bleeding (RD, - 2.54% [95% CI, - 4.53% to - 0.55%]; OR, 0.66 [95% CI, 0.47-0.91]) than the no-OAC cohort. Mortality rates were similar at 30 (OR, 0.87 [95% CI, 0.69-1.08]) and 90 (OR, 1.04 [95% CI, 0.85-1.26]) days. In subgroup analyses, apixaban showed lower ICH and mortality risks than no-OAC.
conclusionDOAC exposure within 1 day before stroke does not result in higher bleeding or mortality risk in patients receiving IVT for acute ischemic stroke.
Indexed as
Identifiers
42332278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.